Quantcast

Jefferson City News

Thursday, October 30, 2025

Bob Onder addresses emergency nurses, FDA drug approval, and potential military pay delays

Webp 0t0inzhcf42mhf18b1idtu3aqo1e

Robert Onder, Member of the U.S. House of Representatives, representing Missouri’s 3rd Congressional District | Official facebook

Robert Onder, Member of the U.S. House of Representatives, representing Missouri’s 3rd Congressional District | Official facebook

Bob Onder, a physician and public official, posted several messages on October 8, 2025, addressing topics ranging from healthcare appreciation to legislative criticism.

In recognition of Emergency Nurses Day, Onder expressed gratitude for emergency nurses. On October 8, he posted, "Today on #EmergencyNursesDay, we honor the heroes who step up when every second counts. Your strength, skill, and compassion save lives every single day - thank you for your unwavering dedication!"

Later that day, Onder commented on the Food and Drug Administration’s decision regarding mifepristone. On October 8, he wrote, "I joined my colleagues in speaking out against the FDA’s approval of mifepristone. As a physician, I know every medication carries risk - and responsible doctors always assess those risks before prescribing." Mifepristone is a medication used for medical abortions, and its approval has been the subject of ongoing political and medical debate.

In another post on October 8, Onder criticized Democratic lawmakers for voting against what he described as a "clean, bipartisan CR" (continuing resolution), warning of consequences for military personnel. He stated, "On October 15, 1.3 million active-duty service members will miss their next paycheck if Democrats keep voting against a clean, bipartisan CR. Our troops don’t deserve this. America doesn’t deserve this. Do the right thing. Open the government." Continuing resolutions are temporary measures used by Congress to fund government operations and avoid shutdowns when formal appropriations bills have not been enacted.

The FDA's approval of mifepristone has been met with opposition from some lawmakers and advocacy groups, who raise concerns about the safety profile of the drug and the regulatory process for its approval. At the same time, government shutdowns resulting from lapses in appropriations can have significant impacts on federal employees and military service members, who may experience delays in pay until funding is restored.

ORGANIZATIONS IN THIS STORY

!RECEIVE ALERTS

The next time we write about any of these orgs, we’ll email you a link to the story. You may edit your settings or unsubscribe at any time.
Sign-up

DONATE

Help support the Metric Media Foundation's mission to restore community based news.
Donate